Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

These are built upon a fortified encoder-decoder structure aimed at providing an automated, streamlined detection mechanism from fundus imagery. Thoroughly tested against the DRIVE, CHASEDB1 and STARE ...

They also will evaluate advances in imaging and current and emerging therapies for the treatment and management of retinal vein occlusion. Upon successful completion of this educational activity ...

In this CE activity, experts in the field will evaluate advances in imaging and current and emerging therapies for the treatment and management of retinal vein occlusion. In support of improving ...

Background Data concerning restenosis following successful recanalization of non-acute internal carotid artery occlusion (ICAO) are scarce. This study was conducted to identify the incidence and ...

To avoid disaster, the Government has limits for legal and illegal drugs, so ask your doctor if you’re unsure. But it’s not just prescription drugs that can see you banned from the steering wheel - ...

The pain worsened, and then her left eye suddenly went completely blind, according to the report. The flight crew decided to make an emergency landing, doctors said, and they were ...

Her right eye looked normal, but doctors saw a transient central retinal artery occlusion — a vessel ... blood vessel that brings blood to your retina, the part of the inner eye that senses ...